BLU:NSD-BELLUS Health Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 9.96

Change

-0.69 (-6.48)%

Market Cap

USD 0.60B

Volume

0.16M

Average Target Price

N/A
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.

Employees : 10

Currency: USD

Country : USA

Technical Indicators

Beta : 0.88

52 Week High : 10.95

Short Ratio : 0.65

52 Week Low : 0.83

Shorted Shares : 194,988

200 Day Moving Average : 7.20

Shorted Shares Previous Month : 180,963

50 Day Moving Average : 8.92

Shares Held By Insiders : 31%

Short Percentage : 0.00%

Shares Held by Institutions : 60%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-02-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-9.28 (-3.77%)

 USD61.45B 52.55 46.39
REGN Regeneron Pharmaceuticals, Inc

+22.23 (+5.51%)

 USD44.35B 21.84 16.87
ALXN Alexion Pharmaceuticals, Inc

-4.12 (-3.99%)

 USD21.92B 9.25 9.18
SGEN Seattle Genetics, Inc

-1.00 (-0.85%)

 USD19.94B N/A -99.92
GLPG Galapagos NV

-28.49 (-10.40%)

 USD17.88B 72.40 0.00
INCY Incyte Corporation

-2.02 (-2.50%)

 USD17.10B 38.47 32.51
BMRN BioMarin Pharmaceutical Inc

-2.16 (-2.27%)

 USD16.71B N/A -338.24
GMAB Genmab A/S

-0.56 (-2.22%)

 USD16.13B N/A -0.00
ALNY Alnylam Pharmaceuticals, Inc

-8.74 (-6.67%)

 USD14.75B N/A -14.66
BGNE BeiGene, Ltd

-5.58 (-3.29%)

 USD13.15B N/A -11.15

ETFs Containing BLU

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 31.05% 84% B 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.05% 84% B 92% A-
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.60B 69% D+ 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -58.75 92% A- 93% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -32.27% 80% B- 29% F
Return on Invested Capital -25.77% 70% C- 24% F
Return on Assets -19.70% 72% C- 21% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.65 80% B- 83% B
Short Percent N/A N/A N/A N/A N/A
Beta 0.88 75% C 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

STA Verdict Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.